ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,687 | +53.3% | 285,000 | +46.2% | 17.16% | +36.8% |
| Q2 2023 | $17,404 | +64.7% | 195,000 | +97.8% | 12.55% | +69.6% |
| Q1 2023 | $10,569 | -42.8% | 98,571 | -34.9% | 7.40% | -17.4% |
| Q4 2022 | $18,492 | -99.9% | 151,409 | +4.3% | 8.95% | -22.1% |
| Q3 2022 | $16,699,000 | +49.7% | 145,209 | +21.0% | 11.49% | +32.8% |
| Q2 2022 | $11,155,000 | -40.8% | 120,000 | -25.2% | 8.65% | -25.0% |
| Q1 2022 | $18,836,000 | +20.8% | 160,500 | +38.5% | 11.54% | +222.7% |
| Q4 2021 | $15,590,000 | +46.6% | 115,885 | +73.7% | 3.58% | -59.6% |
| Q3 2021 | $10,634,000 | +62.6% | 66,714 | +34.2% | 8.85% | +93.7% |
| Q2 2021 | $6,541,000 | +87.5% | 49,721 | +83.7% | 4.57% | +415.7% |
| Q1 2021 | $3,488,000 | -9.8% | 27,064 | +16.7% | 0.89% | -67.5% |
| Q4 2020 | $3,866,000 | – | 23,183 | – | 2.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |